A股首次公开募股的程序是企业迈向资本市场的关键步骤，这个过程包含好几个环节。企业一旦决定要 上市，就必须开始一系列的准备工作。首先需要对自身的财务情况、运营方式等进行彻底的检查和改 进，以便达到上市的基本要求。接着，要依照规定一步步开展各项工作，任何环节都不能有疏忽。从项 目启动到最终在A股市场完成上市，整个环节的每一个环节都必须周密部署并严格遵守各项准则。接下 来，我会具体说明这个步骤。 聘请中介机构这一做法在很多方面都很有价值，中介组织依靠其深厚的学问、广泛的阅历和庞大的社会 关系，能够为有关方面提供各种各样、不同层次的服务和帮助，无论是在生意上的接触阶段，还是在推 进复杂的事情时，中介组织都能发挥其特别的长处，帮助各方更顺利地完成目标，获得最大的好处。借 助专业机构的力量，可以妥善处理各种棘手问题，确保各项工作顺利开展，朝着既定目标前进。 公司想要在A股市场首次公开募股，必须先找上。这类服务公司包括担任推荐人的机构、负责查账验资 的会计单位、提供法律咨询的律所等。中介机构在整个首次公开募股流程中扮演着核心角色，它必须对 企业实施全面细致的审慎核查，透彻了解企业的各项情况，协助企业健全治理架构，让内部运作 ...

据证监会官网显示，中星微技术股份有限公司于2025年8月8日正式启动上市辅导，中国银河证券担任辅 导机构。 ...

Core Viewpoint - China International Capital Corporation (CICC) has released the eighth progress report on the IPO guidance for Shenzhen Chuangxin Laser Co., Ltd, indicating ongoing efforts and challenges in the IPO process [1][4]. Group 1: IPO Guidance Progress - Chuangxin Laser signed a guidance agreement with CICC on July 4, 2023, for its IPO on the Sci-Tech Innovation Board [4]. - CICC completed the filing for guidance with the Shenzhen Regulatory Bureau of the China Securities Regulatory Commission on July 17, 2023, with the eighth phase of guidance covering the period from April 1, 2025, to June 30, 2025 [4]. - The guidance team has focused on monitoring the company's operational performance and reviewing relevant financial reports [4]. Group 2: Existing Challenges - Major issues currently include shareholder verification and fundraising investment projects [5]. - CICC and Chuangxin Laser have established specific verification principles for shareholder transparency and have begun preliminary discussions with shareholders regarding the verification content [5]. - CICC has assisted Chuangxin Laser in initially identifying fundraising investment projects and will continue to urge the company to advance project filing and environmental assessment work [5]. Group 3: Deepening Guidance Content - The content of the guidance has evolved from initial training and governance improvements to a more detailed focus on business development goals, financial management, and industry competition assessment [6]. - The extended timeline for the IPO guidance indicates Chuangxin Laser's patient preparation for the upcoming IPO [6].

Group 1 - The core point of the article is that Yushu Technology is preparing for an IPO, having initiated the listing guidance process with CITIC Securities as the sponsor [2] - Wang Xingxing is the controlling shareholder of Yushu Technology, holding 23.8216% of the shares directly and controlling an additional 10.9414% through a partnership, totaling 34.7630% [2][4] - Yushu Technology is a well-known global company specializing in the research, production, and sales of consumer-grade and industrial-grade robots, including humanoid robots and dexterous robotic arms [2] Group 2 - The company has recently completed a C round of financing, led by major investors including China Mobile's fund, Tencent, Alibaba, and Ant Group, with over 90% participation from existing shareholders [5] - The registered capital of Yushu Technology increased dramatically from 2.889 million to 364 million, reflecting a more than 125-fold increase, indicating significant capital injection [6] - As of July 18, Yushu Technology has over 30 shareholders, with Wang Xingxing as the largest shareholder, followed by Meituan's subsidiary Han Hai Information Technology and Ningbo Sequoia Kesheng Investment [6]

Group 1: Company Developments - Hong Kong Airlines has launched a free airport transfer service in collaboration with 永东直通巴士有限公司 and 日本阿拉丁集团, available until December 31, 2025, for passengers with valid boarding passes [1] - 京东币链科技 has reported that a fake digital currency named JD-HKD has been circulating on major trading platforms, clarifying that no such stablecoin has been issued and urging users to avoid scams [1] - 一亩田集团 has established an international business operation center in Hong Kong, marking the beginning of its global expansion, with active buyers from over 50 countries [2] - 宇树科技 has initiated its listing guidance with 中信证券 as the advisory firm, with its controlling shareholder holding 34.763% of the company [3] - 必和必拓 has announced that its Canadian potash project may exceed budget by $1.7 billion, with the first phase 68% complete and initial production now expected in mid-2027 [4] - 英国石油 has agreed to sell its onshore wind energy business in the U.S. to LS Power [4] - 比亚迪 has established a new sales service company in Jinan, fully owned by its subsidiary [4] - 小米 has officially opened its Shenzhen headquarters, marking its fourth regional headquarters in China [6] - 赛诺菲 has completed the acquisition of Blueprint Medicines for over $9 billion, including a rare disease drug that has been approved in the U.S. and EU [6] - 保泰人寿 has secured $70 million in Series C funding, led by 永明金融有限公司 [6] - 长石资本 has raised 728 million yuan for its hard technology fund, achieving over 50% IPO success rate across its investments [6] Group 2: Product and Partnership Announcements - 腾讯元宝 has integrated with QQ Music, allowing users to play music directly within the app [7] - Airwallex has formed a multi-year global partnership with Arsenal Football Club, becoming the official financial software partner [8] Group 3: Market Insights - The global cryptocurrency market has surpassed $4 trillion for the first time, with Bitcoin accounting for 59.91% of the total market cap at approximately $2.39 trillion [12]

Company News - Yu Shu Technology has initiated its IPO process with China Securities acting as the guidance institution [1] - Wang Xingxing, as the controlling shareholder and actual controller, directly holds 238216% of the company's shares [1] - Wang Xingxing controls a total of 347630% of the company's shares, including direct holdings and indirect control through Shanghai Yu Yi Enterprise Management Consulting Partnership (Limited Partnership) [1]

Group 1 - The core point of the news is the change in the indirect controlling shareholder of Bluestar Medical, with Langhui Petrochemical acquiring a 52.0395% stake, diluting Bluestar Group's stake from 98% to 47.0013% [1] - The company emphasizes that this equity change does not trigger a mandatory takeover, nor does it lead to a change in the controlling shareholder or actual controller, and it will not adversely affect the company's business structure or financial status [1][2] - Langhui Petrochemical, previously a subsidiary of Bluestar Medical, has maintained a close cooperative relationship with the company, being its largest supplier for three consecutive years from 2022 to 2024 [2][3] Group 2 - Langhui Petrochemical initiated its listing guidance in September 2021, with the latest guidance period set from January 1 to March 31, 2025, but faces challenges in internal control and independent director appointments [3] - Bluestar Medical has experienced continuous pressure on its performance over the past three years, with revenues of 4.9 billion, 4.93 billion, and 6.25 billion from 2022 to 2024, and net profits of -372 million, -568 million, and -445 million during the same period [4] - As of May 28, Bluestar Investment holds 235 million shares of Bluestar Medical, accounting for 23.31%, with 183 million shares pledged, representing 18.2% of the total share capital [4]